Linda F. Powers as CYDY's new CEO is something to
Post# of 148179
(Total Views: 766)
Posted On: 05/06/2022 4:01:06 PM
Linda F. Powers as CYDY's new CEO is something to consider.
WHY?
====
As per Ritztheinvestor and USS JOHNSTON posts Ms. Powers checks everyones box. At least read check box [11] which is my favorite point here.
WHO IS MS. POWERS?
====================
Ms. Powers, as current CEO of NWBO one can imagine on 5/10 Phase 3 reveal we learn DCVax®-L for Glioblastoma will have same results of 2 1/2 times longer survival than typical 14+ months survival in the Phase 2 trial. Some patients have a 10 year survival. NEGATIVE: No mention of side effects, no mention that there are little to no side effects <== that is not transparent
WHAT IS GLIOBLASTOMA?
======================
Glioblastoma I understand although rare, is the most prevelant form of brain cancer and, although rare, for unknown reasons is becoming more common.
Here are the boxes MS. POWERS checks off
===================================
[01] woman CEO - may have better credibility under FDA eyes
[02] B.A. Princeton, magna cum laude
[03] J.D. Harvard Law, magna cum laude
[04] ASSUMPTION: will get FDA approval of DCVax®-L for Glioblastoma
[05] We get a partnership without selling out to big pharma (not as great a dilution of our investment)
[06] We get NWBO stock that will still be 50% Leronlimab stock
[07] Leronlimab will get closer to 100% of NWBO's value because of the many indications of much much more prevalant diseases
[08] taught for more than six years at the National Institutes of Health, on medical product development and commercialization, and at Georgetown Law School as an adjunct professor. -- may be able to get funding for multiple LL trials from NIH
[09] previously served as a Managing Director of Toucan Capital Fund II, an investment fund focused on regenerative medicine and immune therapies, from 2001 to 2010
[10] has over 15 years’ experience in corporate finance and restructurings, mergers and acquisitions, joint ventures and intellectual property licensing.
[11] My thinking: upon DCVax®-L FDA aproval -- BOOM! -- Ms. Powers has new credibility and ability to direct CYDY in a manner that focuses on results -- because she has an up to date proven track record at that point <== this is valuable to CYDY shareholders
[12]
[13]
[14]
CONCLUDING COMMENTS
=======================
fill in[12], [13], [14] check boxes, please why don't you.
My only goal here is for CYDY decision makers to consider Ms. Powers
"Side effects reported from early trials are mostly mild"
says https://clinicaltrials.gov/ct2/show/NCT00045968
?? mostly ?? SO we need to ask what are the severe although uncommon side effects? Death or what?
WHY?
====
As per Ritztheinvestor and USS JOHNSTON posts Ms. Powers checks everyones box. At least read check box [11] which is my favorite point here.
WHO IS MS. POWERS?
====================
Ms. Powers, as current CEO of NWBO one can imagine on 5/10 Phase 3 reveal we learn DCVax®-L for Glioblastoma will have same results of 2 1/2 times longer survival than typical 14+ months survival in the Phase 2 trial. Some patients have a 10 year survival. NEGATIVE: No mention of side effects, no mention that there are little to no side effects <== that is not transparent
WHAT IS GLIOBLASTOMA?
======================
Glioblastoma I understand although rare, is the most prevelant form of brain cancer and, although rare, for unknown reasons is becoming more common.
Here are the boxes MS. POWERS checks off
===================================
[01] woman CEO - may have better credibility under FDA eyes
[02] B.A. Princeton, magna cum laude
[03] J.D. Harvard Law, magna cum laude
[04] ASSUMPTION: will get FDA approval of DCVax®-L for Glioblastoma
[05] We get a partnership without selling out to big pharma (not as great a dilution of our investment)
[06] We get NWBO stock that will still be 50% Leronlimab stock
[07] Leronlimab will get closer to 100% of NWBO's value because of the many indications of much much more prevalant diseases
[08] taught for more than six years at the National Institutes of Health, on medical product development and commercialization, and at Georgetown Law School as an adjunct professor. -- may be able to get funding for multiple LL trials from NIH
[09] previously served as a Managing Director of Toucan Capital Fund II, an investment fund focused on regenerative medicine and immune therapies, from 2001 to 2010
[10] has over 15 years’ experience in corporate finance and restructurings, mergers and acquisitions, joint ventures and intellectual property licensing.
[11] My thinking: upon DCVax®-L FDA aproval -- BOOM! -- Ms. Powers has new credibility and ability to direct CYDY in a manner that focuses on results -- because she has an up to date proven track record at that point <== this is valuable to CYDY shareholders
[12]
[13]
[14]
CONCLUDING COMMENTS
=======================
fill in[12], [13], [14] check boxes, please why don't you.
My only goal here is for CYDY decision makers to consider Ms. Powers
"Side effects reported from early trials are mostly mild"
says https://clinicaltrials.gov/ct2/show/NCT00045968
?? mostly ?? SO we need to ask what are the severe although uncommon side effects? Death or what?
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼